Together, these features reinforce the potential benefit of PD-1/PD-L1 blockade for this subtype and highlight the translational relevance of integrated genomic and immunologic biomarkers in stratifying melanoma patients for immunotherapy. This evidence concerns the gene CD274 and melanoma.